darolutamide

{
  "id": "MLC-T-ONC-002285",
  "term": "darolutamide",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with docetaxel to treat adults with certain types of prostate cancer. Darolutamide is used in patients whose cancer has spread to other parts of the body and responds to treatment that lowers testosterone levels or whose cancer has not spread to other parts of the body and no longer responds to treatment that lowers testosterone levels. It is also being studied in the treatment of other types of cancer. Darolutamide binds to proteins called androgen receptors, which are found in some prostate cancer cells. These proteins bind to androgens (male hormones) and may cause cancer cells to grow. Darolutamide blocks these proteins and may keep cancer cells from growing. It is a type of antiandrogen. Also called Nubeqa.",
    "A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells."
  ],
  "synonyms": [
    "Nubeqa",
    "antiandrogen ODM-201"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/darolutamide/"
}